132 related articles for article (PubMed ID: 6498858)
1. alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent.
Hilgard P; Peukert M; Pohl J
Cancer Treat Rev; 1984 Jun; 11(2):115-20. PubMed ID: 6498858
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of the anti tumour activity of new epoxyde derivatives.
Atassi G; Dumont P; Fisher U; Zeidler M; Budnowski M
Cancer Treat Rev; 1984 Mar; 11 Suppl A():99-110. PubMed ID: 6733721
[TBL] [Abstract][Full Text] [Related]
3. Phase-I study of alpha-1,3,5-triglycidyl-s-triazinetrione (NSC 296934).
Dombernowsky P; Lund B; Hansen HH
Cancer Chemother Pharmacol; 1983; 11(1):59-61. PubMed ID: 6883626
[TBL] [Abstract][Full Text] [Related]
4. The analysis and animal pharmacokinetics of 1,2,4, triglycidyl urazol using a high-pressure liquid chromatographic technique.
Welsh J; Stuart JF; Setanoians A; Blackie RG; Billiaert P; Halbert G; Calman KC
Cancer Chemother Pharmacol; 1984; 12(3):198-200. PubMed ID: 6705137
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial with alpha 1,3,5- triglycidyl-s-triazinetrione (NSC-296934).
Piccart M; Rozencweig M; Dodion P; Cumps E; Crespeigne N; Makaroff O; Atassi G; Kisner D; Kenis Y
Eur J Cancer Clin Oncol; 1981 Dec; 17(12):1263-6. PubMed ID: 7200026
[No Abstract] [Full Text] [Related]
6. High-dose 1,2,4-triglycidylurazol given in regimens preparatory to bone marrow transplantation. A preclinical pharmacology study.
Beelen DW; Schilcher RB; Ehrlich R; Quabeck K; Schmidt U; Szy D; Grosse-Wilde H; Becher R; Schaefer UW
Cancer Chemother Pharmacol; 1991; 27(5):361-6. PubMed ID: 1998996
[TBL] [Abstract][Full Text] [Related]
7. Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group.
Bruntsch U; Dodion P; Ten Bokkel Huinink WW; Hansen HH; Pinedo HM; Hansen M; Renard J; Van Glabbeke M
Eur J Cancer Clin Oncol; 1986 Jun; 22(6):697-9. PubMed ID: 3743605
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the activity of alpha/beta-triglycidylurazol (TGU; NSC-332488): a new antineoplastic compound.
Atassi G; Dumont P; Vanhaelen C
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1187-91. PubMed ID: 6541138
[TBL] [Abstract][Full Text] [Related]
9. A characterization of the activity of alpha-1,3,5-triglycidyl-s-triazinetrione, a novel antineoplastic compound.
Spreafico F; Atassi G; Filippeschi S; Malfiore C; Noseda S; Boschetti D
Cancer Chemother Pharmacol; 1980; 5(2):103-8. PubMed ID: 7471313
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic studies of a novel antitumor drug, alpha-1,3,5-triglycidyl-s-triazinetrione. Antitumor and cytotoxic effects.
WU FY; Le Pecq JB
Mol Pharmacol; 1983 Jan; 23(1):182-9. PubMed ID: 6346048
[No Abstract] [Full Text] [Related]
11. A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488).
Cunningham D; Soukop M; Stuart JF; Setanoians A; Gilchrist NL; Forrest GJ; Kaye SB
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1325-9. PubMed ID: 3830214
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral effect in mice of a new triepoxyde derivative: 1, 3, 5-triglycidyl-s-triazinetrione (NSC 296934).
Atassi G; Spreafico F; Dumont P; Nayer P; Klastersky J
Eur J Cancer (1965); 1980 Dec; 16(12):1561-7. PubMed ID: 7227431
[No Abstract] [Full Text] [Related]
13. Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study.
George M; Scotto V; Carnino F; Dodion P; ten Bokkel Huinink WW; Rotmensz N; Vermorken JB
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):867-9. PubMed ID: 3653204
[TBL] [Abstract][Full Text] [Related]
14. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
Slavik M; Blanc O; Davis J
Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870
[TBL] [Abstract][Full Text] [Related]
15. Crystallographic resolution and crystal and molecular structures of stereoisomers of 1,3,5-triglycidyl-s-triazinetrione.
Hempel A; Camerman N; Camerman A
J Med Chem; 1989 Mar; 32(3):648-51. PubMed ID: 2918513
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group.
Rouëssé JG; van Oosterom AT; Capellaere P; Kerbrat P; van Coninge CJ; Thomas D; Benshahar D
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1413-4. PubMed ID: 3678328
[No Abstract] [Full Text] [Related]
17. Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study.
Holdener EE; Clavel M; Sessa C; ten Bokkel Huinink W; Siegenthaler P; Ludwig C; Klepp O; Renard G; Decoster G; Pinedo HM
Eur J Cancer; 1994; 30A(3):394-5. PubMed ID: 8204365
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent.
Hansen SW; Bach F; Hansen HH; Kaplan S; Cavalli F
Eur J Cancer Clin Oncol; 1985 Mar; 21(3):301-5. PubMed ID: 4007009
[TBL] [Abstract][Full Text] [Related]
19. Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
O'Dwyer PJ; Shoemaker D; Zaharko DS; Grieshaber C; Plowman J; Corbett T; Valeriote F; King SA; Cradock J; Hoth DF
Cancer Chemother Pharmacol; 1987; 19(1):6-10. PubMed ID: 3545524
[TBL] [Abstract][Full Text] [Related]
20. The in situ tumour response to combinations of cyclophosphamide and tirapazamine.
Siemann DW
Br J Cancer Suppl; 1996 Jul; 27():S65-9. PubMed ID: 8763849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
